Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Non-Current Debt (2019 - 2025)

Spero Therapeutics' Non-Current Debt history spans 7 years, with the latest figure at $91000.0 for Q4 2025.

  • For Q4 2025, Non-Current Debt changed N/A year-over-year to $91000.0; the TTM value through Dec 2025 reached $91000.0, changed N/A, while the annual FY2025 figure was $91000.0, N/A changed from the prior year.
  • Non-Current Debt reached $91000.0 in Q4 2025 per SPRO's latest filing, up from $13000.0 in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $168000.0 in Q1 2021 to a low of $13000.0 in Q3 2024.
  • Average Non-Current Debt over 5 years is $95812.5, with a median of $93500.0 recorded in 2022.
  • Peak YoY movement for Non-Current Debt: dropped 9.38% in 2023, then tumbled 79.03% in 2024.
  • A 5-year view of Non-Current Debt shows it stood at $138000.0 in 2021, then crashed by 30.43% to $96000.0 in 2022, then decreased by 9.38% to $87000.0 in 2023, then tumbled by 85.06% to $13000.0 in 2024, then skyrocketed by 600.0% to $91000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Non-Current Debt are $91000.0 (Q4 2025), $13000.0 (Q3 2024), and $25000.0 (Q2 2024).